BRCA2 and neuroendocrine carcinoma: While germline BRCA2 mutations are well-established drivers of breast, ovarian, prostate, and pancreatic cancers (13), their role in neuroendocrine carcinoma remains less defined, although they have been reported in prostate, gallbladder, and ovarian NECs (14–16).